SPONSOR
First Affiliated Hospital of Zhejiang University
Total Trials
12
Recruiting
12
Phases
Phase 2, Phase 3
Conditions studied: ADHDImmune SystemClinical SyndromePrecursor B-Cell Acute Lymphoblastic LeukemiaProstate CancerDiffusion MRIRelapsed/Refractory Acute Myeloid LeukaemiaMyeloid MalignancyBile Duct CarcinomaGall Bladder Cancer
First Affiliated Hospital of Zhejiang University is a clinical research sponsor with 12 registered studies on ClinicalTrials.gov, of which 12 are actively recruiting participants. Research covers conditions including ADHD, Immune System, Clinical Syndrome, Precursor B-Cell Acute Lymphoblastic Leukemia.
The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — First Affiliated Hospital of Zhejiang University
How many clinical trials has First Affiliated Hospital of Zhejiang University sponsored?
ClinicalMetric currently tracks 12 clinical trials sponsored by First Affiliated Hospital of Zhejiang University, of which 12 are actively recruiting participants. These trials cover conditions including ADHD, Immune System, Clinical Syndrome. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does First Affiliated Hospital of Zhejiang University research focus on?
First Affiliated Hospital of Zhejiang University clinical trials span ADHD, Immune System, Clinical Syndrome, Precursor B-Cell Acute Lymphoblastic Leukemia, Prostate Cancer, and additional conditions. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a First Affiliated Hospital of Zhejiang University clinical trial?
To participate in a First Affiliated Hospital of Zhejiang University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all First Affiliated Hospital of Zhejiang University trials with current recruitment status updated daily.
Clinical Trials by First Affiliated Hospital of Zhejiang University
NCT06109337
Recruiting
Immunoprofilling of Peripheral Blood Mononuclear Cells in Children With Attention Deficit/Hyperactivity Disorder
ADHD
NCT06754267 Phase 2
Recruiting
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
Precursor B-Cell Acute Lymphoblastic Leukemia
NCT07249281
Recruiting
MR Microstructural Imaging for Prostate Cancer Diagnosis
Prostate Cancer
NCT06621212 Phase 2
Recruiting
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML
Relapsed/Refractory Acute Myeloid Leukaemia
NCT07025174 Phase 2
Recruiting
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Bile Duct Carcinoma
NCT07383818 Phase 2
Recruiting
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
HR Positive/HER2 Low Breast Cancer
NCT07050550
Recruiting
A Prospective Study of ¹⁸F-DFA PET Imaging for the Assessment of Liver Injury
Liver Injury
NCT06114784
Recruiting
Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study
Severe Pneumonia
NCT06361329 Phase 3
Recruiting
Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL
ETP-ALL
NCT07396480 Phase 3
Recruiting
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
Venentoclax
NCT06554626 Phase 2
Recruiting
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
Precursor B-Cell Lymphoblastic Leukemia
NCT06621199 Phase 2
Recruiting
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML
Acute Myeloid Leukemia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology